COMP <GO>
USPH vs JNJ // NET PROFIT MARGIN
U.S. Physical Therapy Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: USPH 4
— JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $85.83 (-0.85%) • MKT CAP: $1.29B
net-margins
5.10%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.20% | 67.90% | -48.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 25.50% | -14.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 18.5x | -2.20 | USPH | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 2.97% | +2.84 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | 34.70% | -23.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 5.10% | 28.50% | -23.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 6.00% | +10.30 | USPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 0.00% | +2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 5.59 | -2.65 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.7 | 62.1 | -7.40 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.4x | 23.0x | +4.40 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $662.49B | -$661.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | JNJ REV | USPH GROSS % | JNJ GROSS % | USPH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $94.19B | 19.2% | 67.9% | $75.1M | $19.70B |
| FY 2024 | $671.3M | $88.82B | 18.5% | 69.1% | $74.9M | $19.84B |
| FY 2023 | $604.8M | $85.16B | — | — | $82.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
JNJ // BETA 1.08